Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥16.08B
• Dividend Yield: N/A
• Average Volume (3M): 467.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: -9.04%
• EPS Growth: 2.12%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -20.19
• Shares Outstanding: 25,679,300
• 10 Day Avg. Volume: 328,590
• 30 Day Avg. Volume: 467,866
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥574.00
• Price Target Upside: -7.12% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ¥590.00 ▼(-4.53% Downside)

Oncolys BioPharma, Inc. receives a low overall score due to significant financial challenges, including declining revenues and persistent losses. Technical indicators show weak momentum, and valuation metrics are poor with a negative P/E ratio. The lack of earnings call data and corporate events further limits positive influences on the score.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Oncolys BioPharma, Inc. generates revenue primarily through research and development collaborations, licensing agreements, and potential milestone payments related to its drug candidates. The company engages in strategic partnerships with larger pharmaceutical firms to jointly develop and commercialize its therapeutic products, which can provide upfront payments, research funding, and potential royalties on sales. Additionally, Oncolys may earn income from government grants and subsidies aimed at supporting innovative biopharmaceutical research. Although the company is still in the development stage, its long-term revenue growth relies on successfully bringing its drug candidates to market, thereby initiating product sales and generating licensing income.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Oncolys BioPharma, Inc. faces serious financial challenges characterized by declining revenues, persistent losses, and negative cash flows. While the balance sheet shows strong equity, the overarching issue is the inability to achieve profitability and positive cash flow, posing risks to long-term viability.

Income Statement

Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.

Balance Sheet

The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.

Cash Flow

Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.38M	31.38M	63.04M	976.18M	642.49M	314.18M
Gross Profit	30.56M	31.38M	30.61M	338.49M	198.80M	236.11M
EBITDA	-2.09B	-1.68B	-1.93B	-1.14B	-1.60B	-2.08B
Net Income	-2.13B	-1.68B	-1.94B	-1.15B	-1.62B	-2.10B
Balance Sheet
Total Assets	2.31B	3.20B	2.04B	2.65B	4.29B	2.80B
Cash, Cash Equivalents and Short-Term Investments	1.74B	2.41B	1.53B	1.71B	3.45B	2.07B
Total Debt	288.78M	324.64M	315.17M	393.66M	503.47M	525.08M
Total Liabilities	373.88M	446.65M	566.50M	491.69M	697.88M	793.09M
Stockholders Equity	1.94B	2.75B	1.47B	2.16B	3.59B	2.00B
Cash Flow
Free Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Operating Cash Flow	0.00	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Investing Cash Flow	0.00	-4.71M	-5.39M	20.12M	-942.00K	-37.58M
Financing Cash Flow	0.00	2.88B	1.14B	-113.83M	3.09B	242.26M

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 618.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Negative. The current price of 618 is below the 20-day moving average (MA) of 633.50, below the 50-day MA of 636.38, and above the 200-day MA of 609.70, indicating a neutral trend. The MACD of -7.87 indicates Positive momentum. The RSI at 45.60 is Neutral, neither overbought nor oversold. The STOCH value of 40.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	66 Neutral	11.48B	-229.22	3.94%	0.86%	-13.81%	-107.95%
4888	50 Neutral	12.35B	-91.02	-4.39%	―	268.05%	83.57%
4583	48 Neutral	9.12B	-8.55	―	―	30.92%	26.00%
4579	47 Neutral	14.19B	-24.80	-8.37%	―	40.66%	24.86%
4599	47 Neutral	18.83B	-9.73	―	―	―	5.59%
4588	41 Neutral	¥16.08B	―	―	―	-9.04%	2.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Increased Losses in H1 2025

Oncolys BioPharma Inc. reported its non-consolidated financial results for the first half of 2025, revealing a decline in net sales and increased losses compared to the previous year. The company’s net sales dropped to 28 million yen, with operating and ordinary profits showing significant negative figures. Despite the challenging financial performance, the company maintains a strong equity ratio, although its total assets and net assets have decreased. The financial results indicate ongoing challenges in the company’s operations, which may impact its market positioning and stakeholder confidence.